טוען...
Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
OBJECTIVE: To estimate the risk of progressive multifocal leukoencephalopathy (PML) and the safety of natalizumab administration in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: A descriptive retrospective observational study including all patients with RRMS treated with nata...
שמור ב:
| הוצא לאור ב: | Eur J Hosp Pharm |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMJ Publishing Group
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7907687/ https://ncbi.nlm.nih.gov/pubmed/33608441 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2019-002048 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|